Anika Therapeutics Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 10/11/2026)
| Balance Sheet | Total Assets | 190,270,000.00 | ROE | 75.40 % |
| Balance Sheet | Total Equity | 143,465,000.00 | ROA | -5.72 % |
| Cashflow | Capital Expenditures | -6,826,000.00 | P/FCF | 66.57 |
| Cashflow | Free Cash Flow | 4,362,000.00 | – | – |
| Cashflow | Operating Cash Flow | 11,188,000.00 | P/CF | 25.95 |
| Income | Earnings per Share (diluted) | -0.76 | Div. Yield | – |
| Income | Net Income | -10,880,000.00 | P/E | -26.64 |
| Income | Shares Outstanding | 14,339,000.00 | P/B | 2.02 |
| Income | Total Revenue | 112,819,000.00 | P/S | 2.57 |
Ratios calculated on: 10/14/2026
Company Description
Anika Therapeutics, Inc. (Anika) develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. As of December 31, 2011, Anika´s wholly owned subsidiary, Anika Therapeutics S.r.l., had over 20 products commercialized, primarily in Europe. These products are also all made from hyaluronic acid, based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.anikatherapeutics.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more